Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

Inclusion Criteria: PWH: * Age ≥18 years, patient receiving care at partnering clinical sites; * can identify a support person injector (i.e., family, friend, or partner) who is willing and able to provide injections; * has received at least the loading dose of cabotegravir/rilpivirine CAB/RPV (i.e., 600mg/900mg IM) without serious adverse events; * is virologically suppressed (HIV RNA \<50 copies/mL); * has no history of treatment failure; * has no known or suspected resistance to either RPV or CAB; * is interested in receiving home-based injections; is approved by their clinical team as a candidate for home-based injections; * has the intention to use CAB/RPV for at least 12 months; * and is willing and able to give informed consent. Treatment Buddy: * Age ≥18 years, * identified by the PWH, * is willing and able to provide monthly or bimonthly LAI-ART injections at the PWH's place of residence, and * is willing and able to give informed consent. Exclusion Criteria: PWH: * \<18 years of age, not receiving care at partnering clinic sites, * cannot identify a support person injector, * has not received at least the loading dose of CAB/RPV, * had serious adverse events with CAB/RPV with the loading dose, * is not virologically suppressed, * has a history of treatment failure, * has a known or suspected resistance to either RPV or CAB, * is not interested in receiving home-based injections, * is not approved but their clinical team as a candidate for home-based injection…